Online inquiry

IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12371MR)

This product GTTS-WQ12371MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SAA1 gene. The antibody can be applied in AA amyloidosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000331.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6288
UniProt ID P0DJI8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12371MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3534MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ3359MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ15072MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
GTTS-WQ8482MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2702MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ5170MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ7119MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ1978MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGS-15E
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW